Cargando…

Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial

INTRODUCTION: Postpartum depression affects 10%–15% of women and has a recurrence rate of 40% in subsequent pregnancies. Women who develop postpartum depression are suspected to be more sensitive to the rapid and large fluctuations in sex steroid hormones, particularly estradiol, during pregnancy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Høgh, Stinne, Hegaard, Hanne Kristine, Renault, Kristina Martha, Cvetanovska, Eleonora, Kjærbye-Thygesen, Anette, Juul, Anders, Borgsted, Camilla, Bjertrup, Anne Juul, Miskowiak, Kamilla Woznica, Væver, Mette Skovgaard, Stenbæk, Dea Siggaard, Dam, Vibeke Høyrup, Binder, Elisabeth, Ozenne, Brice, Mehta, Divya, Frokjaer, Vibe G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719185/
https://www.ncbi.nlm.nih.gov/pubmed/35763351
http://dx.doi.org/10.1136/bmjopen-2021-052922
_version_ 1784624882829492224
author Høgh, Stinne
Hegaard, Hanne Kristine
Renault, Kristina Martha
Cvetanovska, Eleonora
Kjærbye-Thygesen, Anette
Juul, Anders
Borgsted, Camilla
Bjertrup, Anne Juul
Miskowiak, Kamilla Woznica
Væver, Mette Skovgaard
Stenbæk, Dea Siggaard
Dam, Vibeke Høyrup
Binder, Elisabeth
Ozenne, Brice
Mehta, Divya
Frokjaer, Vibe G
author_facet Høgh, Stinne
Hegaard, Hanne Kristine
Renault, Kristina Martha
Cvetanovska, Eleonora
Kjærbye-Thygesen, Anette
Juul, Anders
Borgsted, Camilla
Bjertrup, Anne Juul
Miskowiak, Kamilla Woznica
Væver, Mette Skovgaard
Stenbæk, Dea Siggaard
Dam, Vibeke Høyrup
Binder, Elisabeth
Ozenne, Brice
Mehta, Divya
Frokjaer, Vibe G
author_sort Høgh, Stinne
collection PubMed
description INTRODUCTION: Postpartum depression affects 10%–15% of women and has a recurrence rate of 40% in subsequent pregnancies. Women who develop postpartum depression are suspected to be more sensitive to the rapid and large fluctuations in sex steroid hormones, particularly estradiol, during pregnancy and postpartum. This trial aims to evaluate the preventive effect of 3 weeks transdermal estradiol treatment immediately postpartum on depressive episodes in women at high risk for developing postpartum depression. METHODS AND ANALYSIS: The Maternal Mental Health Trial is a double-blind, randomised and placebo-controlled clinical trial. The trial involves three departments of obstetrics organised under Copenhagen University Hospital in Denmark. Women who are singleton pregnant with a history of perinatal depression are eligible to participate. Participants will be randomised to receive either transdermal estradiol patches (200 µg/day) or placebo patches for 3 weeks immediately postpartum. The primary outcome is clinical depression, according to the Diagnostic and Statistical Manual of Mental Disorders-V criteria of Major Depressive Disorder with onset at any time between 0 and 6 months postpartum. Secondary outcomes include, but are not limited to, symptoms of depression postpartum, exclusive breastfeeding, cortisol dynamics, maternal distress sensitivity and cognitive function. The primary statistical analysis will be performed based on the intention-to-treat principle. With the inclusion of 220 participants and a 20% expected dropout rate, we anticipate 80% power to detect a 50% reduction in postpartum depressive episodes while controlling the type 1 error at 5%. ETHICS AND DISSEMINATION: The study protocol is approved by the Regional Committees on Health Research Ethics in the Capital Region of Denmark, the Danish Medicines Agency and the Centre for Data Protection Compliance in the Capital Region of Denmark. We will present results at scientific meetings and in peer-reviewed journals and in other formats to engage policymakers and the public. TRIAL REGISTRATION NUMBER: NCT04685148.
format Online
Article
Text
id pubmed-8719185
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-87191852022-01-12 Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial Høgh, Stinne Hegaard, Hanne Kristine Renault, Kristina Martha Cvetanovska, Eleonora Kjærbye-Thygesen, Anette Juul, Anders Borgsted, Camilla Bjertrup, Anne Juul Miskowiak, Kamilla Woznica Væver, Mette Skovgaard Stenbæk, Dea Siggaard Dam, Vibeke Høyrup Binder, Elisabeth Ozenne, Brice Mehta, Divya Frokjaer, Vibe G BMJ Open Mental Health INTRODUCTION: Postpartum depression affects 10%–15% of women and has a recurrence rate of 40% in subsequent pregnancies. Women who develop postpartum depression are suspected to be more sensitive to the rapid and large fluctuations in sex steroid hormones, particularly estradiol, during pregnancy and postpartum. This trial aims to evaluate the preventive effect of 3 weeks transdermal estradiol treatment immediately postpartum on depressive episodes in women at high risk for developing postpartum depression. METHODS AND ANALYSIS: The Maternal Mental Health Trial is a double-blind, randomised and placebo-controlled clinical trial. The trial involves three departments of obstetrics organised under Copenhagen University Hospital in Denmark. Women who are singleton pregnant with a history of perinatal depression are eligible to participate. Participants will be randomised to receive either transdermal estradiol patches (200 µg/day) or placebo patches for 3 weeks immediately postpartum. The primary outcome is clinical depression, according to the Diagnostic and Statistical Manual of Mental Disorders-V criteria of Major Depressive Disorder with onset at any time between 0 and 6 months postpartum. Secondary outcomes include, but are not limited to, symptoms of depression postpartum, exclusive breastfeeding, cortisol dynamics, maternal distress sensitivity and cognitive function. The primary statistical analysis will be performed based on the intention-to-treat principle. With the inclusion of 220 participants and a 20% expected dropout rate, we anticipate 80% power to detect a 50% reduction in postpartum depressive episodes while controlling the type 1 error at 5%. ETHICS AND DISSEMINATION: The study protocol is approved by the Regional Committees on Health Research Ethics in the Capital Region of Denmark, the Danish Medicines Agency and the Centre for Data Protection Compliance in the Capital Region of Denmark. We will present results at scientific meetings and in peer-reviewed journals and in other formats to engage policymakers and the public. TRIAL REGISTRATION NUMBER: NCT04685148. BMJ Publishing Group 2021-12-30 /pmc/articles/PMC8719185/ /pubmed/35763351 http://dx.doi.org/10.1136/bmjopen-2021-052922 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Mental Health
Høgh, Stinne
Hegaard, Hanne Kristine
Renault, Kristina Martha
Cvetanovska, Eleonora
Kjærbye-Thygesen, Anette
Juul, Anders
Borgsted, Camilla
Bjertrup, Anne Juul
Miskowiak, Kamilla Woznica
Væver, Mette Skovgaard
Stenbæk, Dea Siggaard
Dam, Vibeke Høyrup
Binder, Elisabeth
Ozenne, Brice
Mehta, Divya
Frokjaer, Vibe G
Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial
title Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial
title_full Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial
title_fullStr Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial
title_full_unstemmed Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial
title_short Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial
title_sort short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled mama clinical trial
topic Mental Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719185/
https://www.ncbi.nlm.nih.gov/pubmed/35763351
http://dx.doi.org/10.1136/bmjopen-2021-052922
work_keys_str_mv AT høghstinne shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT hegaardhannekristine shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT renaultkristinamartha shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT cvetanovskaeleonora shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT kjærbyethygesenanette shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT juulanders shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT borgstedcamilla shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT bjertrupannejuul shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT miskowiakkamillawoznica shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT vævermetteskovgaard shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT stenbækdeasiggaard shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT damvibekehøyrup shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT binderelisabeth shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT ozennebrice shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT mehtadivya shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial
AT frokjaervibeg shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial